Hi! Biopharma already had a trust problem before the new administration. Now, with direction and decision-making being so-called streamlined and centralized at HHS, it seems the public’s trust in healthcare – the governing bodies, scientific and medical advances, and the industry as a whole – is plummeting. How does this chaotic landscape factor into how we do our job as communicators? How does the absence of trust hinder our ability to fulfill our role? How do we build trust with executives, clients, or other key stakeholders who see communications as a “nice to have” rather than a strategic function? You’ll have your own thoughts about the answers to those questions, and in tomorrow’s Comm Convo – The Trust Exchange – you’ll hear how Kris Baum (former FDA, CDER), Mary Kosinski (FleishmanHillard), and Sarah Spencer (Vor Bio) feel about the current state of trust in the biopharma industry. Sign up hereT2B Pro & Student members (FREE): Log in to your account, and get your promo code here. T2B Basic members ($40): RSVP and secure your place here. What you can expectWith perspectives from in-house, agency partner, and government, this session will open a practical discussion about strengthening the relationships that matter most, both inside and outside your organization, so that you can:
Trust goes both ways. From talking to many of our T2B community members, we know that in the current climate, you’re also struggling to decipher what information is reputable and which organizations you can trust. You’ve asked us if we still have hope for the industry, and if so, where we’re getting it from. The answer is that we do. We believe that together, we can get past this turbulent time and build trusting professional relationships with all key stakeholders. We’ll tell you “how” tomorrow! Lynnea |
Hi! The outcomes of the annual American Society of Clinical Oncology (ASCO) meeting will flood the media landscape with clinical updates, milestone announcements, and analyst notes. So biopharma comms pros and storytellers must understand how to stand out during one of healthcare’s most concentrated news moments. Enter the Q2 Media Minds Panel: Oncology Reporting and ASCO Coverage. “Top-Tier Perspective on ASCO and Beyond: How to Stand Out During Concentrated News Moments” is happening...
Hi! Last week, the T2B community tackled the topic of trust. In an intriguing and very candid Comm Convo led by speakers Kris Baum (former FDA, CDER), Mary Kosinski (FleishmanHillard), and Sarah Spencer (Vor Bio), we explored how the relationships we build shape our ability to lead, influence, and respond. With so many specific anecdotes and practical tips shared, it was hard to narrow down to just 10 key takeaways, but we managed it (barely!): Leverage science as your trust anchor. When...
Hi! We’re all about bringing together the most creative minds in biopharma in a bid to secure and enhance the future of our profession. One of the many ways we do this is through our roundtables, which are driven directly by members who specialize in, and are passionate about, key areas of biopharma communications. And the next discipline on that roster is patient advocacy and engagement. Everything you need to know about the Patient Advocacy and Engagement Roundtable This roundtable will...